Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2010 - 2026)

Lineage Cell Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 29.34% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$53.1 million (down 181.68% YoY), while the FY2025 annual figure was -$63.4 million, down 241.01% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$4.8 million, up from -$6.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$3.0 million in Q3 2024, with the low at -$22.5 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is -$6.3 million (2022), against an average of -$7.4 million.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 77.43% in 2022, then plunged 528.02% in 2025.
• Lineage Cell Therapeutics' Net Income towards Common Stockholders stood at -$6.3 million in 2022, then increased by 25.42% to -$4.7 million in 2023, then jumped by 31.06% to -$3.2 million in 2024, then slumped by 110.98% to -$6.9 million in 2025, then gained by 29.82% to -$4.8 million in 2026.
• Business Quant data shows LCTX's Net Income towards Common Stockholders at -$4.8 million in Q1 2026, -$6.9 million in Q4 2025, and -$18.8 million in Q3 2025.